Clinical outcome of cord blood transplantation for nine children with juvenile myelomonocytic leukemia receiving fludarabine‐busulfan‐cyclophosphamide‐based conditioning

• Published in: Pediatric transplantation 2022-03, Vol.26 (2), p.e14181-n/a
• Main Authors: Li, Guifang, Sun, Zimin, Geng, Liangquan, Wan, Xiang, Zhu, Xiaoyu, Tang, Baolin, Tong, Juan, Yao, Wen, Song, Kaidi, Qiang, Ping, Zhang, Lei, Zhang, Xuhan, Zhang, Shiyang, Liu, Huilan
• Format: Article
• Language: English
• Subjects: Antineoplastic Agents - administration & dosage; Busulfan; Busulfan - administration & dosage; Child; Child, Preschool; Children; China; Clinical outcomes; conditioning regimen; Cord blood; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cyclophosphamide - administration & dosage; Fludarabine; Humans; Infant; juvenile myelomonocytic leukemia; Leukemia; Leukemia, Myelomonocytic, Juvenile - therapy; Male; Malignancy; Myelomonocytic leukemia; Patients; Remission; Retrospective Studies; Stem cell transplantation; Transplantation Conditioning - methods; umbilical cord blood transplant; Vidarabine - administration & dosage; Vidarabine - analogs & derivatives
• ISSN: 1397-3142; 1399-3046
• DOI: 10.1111/petr.14181

Background Juvenile myelomonocytic leukemia (JMML) is a rare hematological malignancy in young children and can only be cured through the allogeneic stem cell transplantation. Procedure We have retrospectively analyzed the outcomes of nine children with JMML after unrelated cord blood transplantation (UCBT). Results Eight patients who have received a myeloablative conditioning regimen of fludarabine (FLU), busulfan (BU), and cyclophosphamide (CY) have gotten engraftment. None of the nine patients has relapsed following initial UCBT. Six patients are still alive and in complete remission after UCBT with a median observation time of 43 months (range: 10–80 months). Conclusions This study shows that UCBT with FLU‐BU‐CY conditioning regimen can represent a suitable option for children with JMML.